小儿及成年癫痫患者血浆中的地西泮结合抑制剂（DBI）

Diazepam binding inhibitor (DBI) in the plasma of pediatric and adult epileptic patients.

作者信息

Ferrarese C, Cogliati T, Tortorella R, Zucca C, Bogliun G, Beghi E, Passoni D, Zoia C, Begni B, Airoldi L, Alho H, Frattola L

机构信息

Scientific Institute E. Medea, Bosisio Parini, Lecco, Italy.

出版信息

Epilepsy Res. 1998 Jan;29(2):129-34. doi: 10.1016/s0920-1211(97)00074-0.

DOI:10.1016/s0920-1211(97)00074-0

PMID:9477145

Abstract

The polypeptide diazepam binding inhibitor (DBI) displays epileptogenic activity by binding to benzodiazepine receptors. We analyzed DBI concentrations in the plasma of pediatric and adult epileptic patients, as a possible peripheral marker in epilepsy. DBI plasma concentrations are significantly higher (+ 62%, P < 0.001) in adult patients and slightly but significantly higher (+15%, P < 0.01) in pediatric patients, compared to age-related controls. Strikingly, plasma DBI is much higher (+81%, P < 0.001) in generalized epilepsy in adults and in drug-resistant pediatric and adult patients. Based on these findings, plasma DBI may be considered as a peripheral biological marker of epilepsy and, in association with lymphocyte benzodiazepine receptor density, of anticonvulsant drug responsiveness.

摘要

多肽类地西泮结合抑制剂（DBI）通过与苯二氮䓬受体结合而表现出致癫痫活性。我们分析了小儿和成人癫痫患者血浆中的DBI浓度，将其作为癫痫可能的外周标志物。与年龄匹配的对照组相比，成人患者的DBI血浆浓度显著更高（升高62%，P<0.001），小儿患者的DBI血浆浓度虽略有升高但也显著升高（升高15%，P<0.01）。引人注目的是，成人全身性癫痫患者以及耐药的小儿和成人患者的血浆DBI水平更高（升高81%，P<0.001）。基于这些发现，血浆DBI可被视为癫痫的外周生物学标志物，并且与淋巴细胞苯二氮䓬受体密度相关，可作为抗惊厥药物反应性的标志物。